Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Hamilton

Physician Assistant, Medical Bel Air, MD Physician Assistant

NPI 1215376124 CMS profile 10625813

12 Medstar Blvd, Bel Air, MD 21015

Open in the dashboard

General payments

$51,975

616 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Hamilton of Bel Air, MD is reported in the CMS Open Payments database as having received $51,975 across 616 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $32,670 197
2024 General $15,091 219
2023 General $1,642 85
2022 General $2,105 99
2021 General $468 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Hamilton
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jennifer Hamilton were reported at $32,670. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jennifer Hamilton Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $468 $156 $41–$563 $132
2022 $2,105 $185 $55–$649 $149
2023 $1,642 $199 $58–$717 $160
2024 $15,091 $206 $62–$740 $164
2025 $32,670 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $30,521 116 payments
  2. Phathom Pharmaceuticals, Inc. $10,544 42 payments
  3. AbbVie, Inc. $2,922 171 payments
  4. Merck Sharp & Dohme Corporation $1,246 12 payments
  5. Madrigal Pharmaceuticals $1,044 20 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $787 41 payments
  7. Regeneron Healthcare Solutions, Inc. $665 36 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $600 24 payments
  9. Ardelyx, Inc. $533 22 payments
  10. Pfizer Inc. $391 20 payments
  11. Other $2,722 112 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,521 14 payments
  2. Food and Beverage $14,236 574 payments
  3. Travel and Lodging $8,509 22 payments
  4. Consulting Fee $4,463 1 payment
  5. Education $246 5 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $30,059 92 payments
  2. VOQUEZNA $10,340 30 payments
  3. STELARA $1,649 37 payments
  4. LINZESS $972 49 payments
  5. RINVOQ $942 69 payments
  6. REZDIFFRA $890 18 payments
  7. CREON $849 46 payments
  8. VIBERZI $736 35 payments
  9. XIFAXAN $647 31 payments
  10. DUPIXENT $575 32 payments
  11. Other $7,055 344 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

456

Median for Physician Assistant: 241

Drug cost

$217,019

Median for Physician Assistant: $4,110

Branded share of claims

24.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 27 $94,575
Xifaxan Rifaximin Brand 25 $57,072
Linzess Linaclotide Brand 35 $42,537
Motegrity Prucalopride Succinate Brand 15 $10,347
Colestipol Hcl Generic 43 $3,729
Famotidine Generic 114 $3,322
Pantoprazole Sodium Generic 97 $2,797
Mesalamine Er Mesalamine Brand 11 $630
Esomeprazole Magnesium Generic 17 $620
Dicyclomine Hcl Generic 27 $574

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$61,134

Medicare's payments for the services billed

Medicare patients

467

Average age 75

Services billed

679

346 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 34%
Depression 31%
Diabetes 26%
Osteoporosis 24%
Chronic kidney disease 21%
Cancer 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$6,129 — —
TREMFYA
$5,518 — —
STELARA
$306 — —
IBSRELA
$297 — —
LINZESS
$288 35 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

616 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record